Table of contents


On 14 October 2016, orphan designation (EU/3/16/1758) was granted by the European Commission to Clinical Network Services (UK) Ltd, United Kingdom, for P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide for the treatment of acute myeloid leukaemia.

The sponsorship was transferred to Clinical Network Services (NL) B.V., The Netherlands, in January 2019.

In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.

Key facts

Active substance
P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
EU designation number

Sponsor's contact details

Scendea (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
The Netherlands
Tel. +31 2089 49169

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating